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ABSTRACT:
The widely prescribed lipid-lowering statins are considered to be
relatively safe drugs. However, the risk of severe myopathy and drug
interactions as a consequence of statin therapy provides a challenge
for development of novel cholesterol-lowering agents, targeting
enzymes other than HMG-CoA reductase. The novel pyridylethanol-
(phenylethyl)amine derivative, (2-((3,4-dichlorophenethyl)(propyl)-
amino)-1-(pyridin-3-yl)ethanol (LK-935), blocking lanosterol 14-
demethylase, was demonstrated to efficiently reduce cholesterol
biosynthesis. The drug interaction potential of LK-935 was inves-
tigated and compared with that of atorvastatin and rosuvastatin in
primary human hepatocytes. Clear evidence was provided for the
induction of CYP3A4 by LK-935. LK-935 was proved to be a potent
human pregnane X receptor (hPXR) activator as a prerequisite for
the transcriptional activation of CYP3A4 gene; however, the rapid
metabolism of LK-935 in primary hepatocytes prevented maximal
CYP3A4 induction. Therefore, the induction of CYP3A4 by LK-935
may be prone to mild or negligible drug interactions. However,
because CYP3A4 and also CYP2C9 play a significant role in LK-935
metabolism, the inhibition of these cytochromes P450 by coadmin-
istered drugs may lead to some increase in the LK-935 concentra-
tion required for the potent induction of CYP3A4. Rosuvastatin was
found to increase human constitutive androstane receptor (hCAR)-
mediated transcription of CYP3A4, CYP2C9, and CYP2B6 genes,
predicting the consequent potential for drug interactions with sev-
eral coadministered drugs. Activation of hCAR and hPXR by ator-
vastatin and the subsequent induction of not only CYP2B6 and
CYP3A4 but also of CYP2C9 present an additional target by which
atorvastatin, a widely used cholesterol-lowering drug, can modify
the kinetics of numerous drugs.
Cardiovascular disease is one of the major causes of mortality in the
developed world. The imbalance of cholesterol homeostasis and a
high plasma concentration of low-density lipoprotein-cholesterol are
risk factors for cardiovascular diseases (atherosclerosis, coronary
heart disease, and myocardial infarction). Therefore, cholesterol-low-
ering therapy is essential for prevention of the progression of choles-
terol-laden plaques in vessel linings (Maas and Bo¨ger, 2003; LaRosa,
2007). Lipid-modifying therapy to decrease elevated cholesterol con-
centrations constitutes the inhibition of de novo cholesterol biosyn-
thesis in the liver and the decrease of the dietary cholesterol uptake
from intestine (LaRosa, 2007; Bays et al., 2008; Koh et al., 2008;
Sanossian and Ovbiagele, 2008). The most commonly prescribed
cholesterol-lowering agents are the statins, the HMG-CoA reductase
inhibitors (Rallidis et al., 2007). Competitive inhibition of HMG-CoA
reductase by the statins efficiently decreases the conversion of HMG-
CoA to mevalonate, the rate-limiting step of cholesterol biosynthesis
(Fig. 1A). Even if the lipid-lowering statins are still considered to be
relatively safe drugs that are taken by millions of patients worldwide,
considerable attention has been paid recently to the statin-based risk
of muscular adverse drug reactions and hepatotoxicity (Martin and
Krum, 2007). Although officially only 2 to 3% of patients get muscle
aches and cramps, considering that 5 to 10% of the population in
developed societies are treated with statins, this occurrence represents
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a major health risk problem for development of severe myopathies,
rhabdomyolysis, impaired cognitive function, and nephropathies and
can even lead to death (Tiwari et al., 2006; Alsheikh-Ali et al., 2007;
Armitage, 2007; Rallidis et al., 2007).
Almost all statins used clinically have been reported to interact with
the cytochrome P450 (P450) enzymes, leading to pharmacokinetic
interactions with coadministered drugs (Shitara and Sugiyama, 2006).
Lovastatin, simvastatin, and atorvastatin are both substrates and in-
hibitors of human CYP3A4, the main drug-metabolizing P450 en-
zyme, whereas CYP2C9 is the target of drug interactions caused by
fluvastatin (Beaird, 2000; Shitara and Sugiyama, 2006). Approxi-
mately 60% of cases of statin-related rhabdomyolysis have been
attributed to drug-drug interactions (Muscari et al., 2002; Sica and
Gehr, 2002; Neuvonen et al., 2006; Tiwari et al., 2006). On the other
hand, many compounds that are substrates for P450s also induce the
transcription of P450 genes, resulting in elevated enzyme levels and
metabolic functions. HMG-CoA reductase inhibitors have been
proved to increase the expression of several P450s. Cerivastatin,
simvastatin, atorvastatin, and fluvastatin have been shown to activate
human constitutive androstane receptor (hCAR) and pregnane X
receptor (PXR) and consequently to increase the transcription of the
target genes, CYP2B6 and CYP3A4 (El-Sankary et al., 2001; Kocarek
et al., 2002; Kobayashi et al., 2005). In contrast to these statins,
pravastatin does not seem to interact with the P450 system, does not
inhibit it substantially, and does not induce the transcription of P450
genes, possibly because of its hydrophilic nature (Beaird, 2000; El-
Sankary et al., 2001; Schachter, 2004; Neuvonen et al., 2006).
It has been reported that derangements in mevalonate kinase but not
in more distal enzymes of cholesterologenesis are associated with the
skeletal myopathy provoked by statins (Buhaescu and Izzedine,
2007). By inhibition of the major regulatory enzyme of cholesterol
biosynthesis, HMG-CoA reductase, statins also decrease the level of
an essential metabolite, coenzyme Q (Fig. 1A), which probably con-
tributes to muscle-related complications. Thus, the development of
novel cholesterol-lowering agents, targeting enzymes below the far-
nesyl pyrophosphate branchpoint of cholesterol biosynthesis, offers
the possibility for the elimination of some adverse effects. The lanos-
terol 14-demethylase CYP51 is a potential anticholesterolemic drug
target. CYP51 is responsible for the removal of the 14-methyl of
lanosterol and 24,25-dihydrolanosterol to produce follicular fluid mei-
osis activating sterol (FF-MAS) (Stromstedt et al., 1996; Debeljak et
al., 2003). A novel pyridylethanol(phenylethyl)amine derivative, LK-
935 developed by Lek Pharmaceuticals d.d. (Ljubljana, Slovenia) has
been identified as a postlanosterol cholesterol biosynthesis inhibitor.
Structure-activity relationship studies of the binding with overex-
pressed human CYP51 indicate that the pyridine binds within the
heme pocket in an analogy with azoles (Korosec et al., 2008).
The goal of the present study was to investigate whether the drug
interaction potential of the statin-based cholesterol-lowering therapy
could be eliminated by using the CYP51-targeted LK-935. The P450-
inducing capacity of LK-935 was examined in primary cultures of
human hepatocytes and compared with that of atorvastatin and rosu-
vastatin. We provided evidence for a role of hPXR in the induction of
the CYP3A4 gene by LK-935. We also attempted to explain the
contradiction of the strong PXR activation potential and the weak
CYP3A4-inducing capacity exerted by LK-935.
Materials and Methods
Chemicals. LK-935, atorvastatin, and rosuvastatin were provided by Lek
Pharmaceuticals d.d. Rifampicin and dimethyl sulfoxide were the products of
Sigma Chemie GmbH (Deisenhofen, Germany). Chemicals for hepatocyte
isolation, cell culture media, and supplements were purchased from Sigma
Chemie GmbH and Merck (Darmstadt, Germany). Commercial and laboratory
sterol standards, lanosterol, lathosterol, 7-dehydrocholesterol, desmosterol,
cholesterol, and FF-MAS, were obtained from Steraloids (Newport, RI) and
Laboratory of Reproductive Biology (The Juliane Marie Center for Children,
Women and Reproduction, University Hospital of Copenhagen, Copenhagen,
Denmark). [3H]Acetate was purchased from PerkinElmer Life and Analytical
Sciences (Waltham, MA).
Sterol Profile Analysis in HepG2 Cells. Human hepatoma cells (HepG2,
No. HB-8065; American Type Culture Collection, Manassas, VA) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
5% fetal calf serum and 1 mM glutamine. After 24 h, the medium was changed,
and the cells were treated for 24 h with LK-935 (10 M) and atorvastatin (10
M) or rosuvastatin (10 M) as the reference controls. The growth medium
was replaced, and [3H]acetate was added in a concentration of 40 Ci/ml.
After a 4-h incubation, the cells were harvested, washed, and homogenized.
The internal standard ergosterol (0.25 mg/ml) was added before the extraction
procedure. After addition of 0.3 M NaH2PO4 (pH 1.0), sterols were extracted
in n-heptane-isopropanol (75:25 v/v) from cell homogenates. The organic
phases were dried and dissolved in n-heptane. The samples were analyzed by
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FIG. 1. The action of hypolipidemic statins and LK-935 in de novo biosynthesis of
cholesterol. A, the main intermediates and the sites of inhibition by statins and
LK-935 are shown in the cholesterol biosynthesis pathway. B, HepG2 cells were
treated for 24 h with statins (10 M) and LK-935 (10 M). The amounts of sterol
intermediates were determined after a 4-h incubation with [3H]acetate. Controls for
each independent experiment were assigned values of 1 and the results of treatments
are expressed relative to the controls. CoQ-10, coenzyme Q; nd, not detectable.
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high-performance liquid chromatography (radiodetection) for quantitation of
lanosterol, FF-MAS, lathosterol, 7-dehydrocholesterol, desmosterol, and cho-
lesterol using a Prism-RPN (250  4.6 mm, 5 m column; Thermo Fisher
Scientific Inc., Waltham, MA) and the mobile phase of 100% acetonitrile. The
column was eluted at a rate of 1 ml/min at 40°C, and the effluent was analyzed
by flow scintillation using an on-line radioactivity detector. The amounts of
various sterols were normalized on ergosterol quantity and protein concentra-
tion. Three separate experiments with two replicas were performed. The results
were expressed as the amounts of sterols in treated cells relative to untreated
cells.
Isolation and Culture of Human Hepatocytes. Human livers (HH-089,
HH-114, HH-129, and HH-272) were obtained from kidney transplant donors
or from lobectomy segments (HH-269, HH-270, and HH-271) resected from
adult patients for medical reasons unrelated to our research program (Trans-
plantation and Surgical Clinic, Semmelweis University, Budapest, Hungary,
and Centre Hospitalier Universitaire, Saint-Eloi, Montpellier, France). Permis-
sion to use the human tissues was obtained from the Hungarian and French
Regional Committee of Science and Research Ethics. Clinical histories of the
donors are shown in Table 1. Liver cells were isolated by the method of Bayliss
and Skett (1996). Hepatocytes having viability better than 90%, as determined
by trypan blue exclusion, were used in the experiments. The cells were plated
at a density of 1.7  105 cells/cm2 in plastic dishes precoated with collagen in
medium described by Ferrini et al. (1998). After overnight culture, the medium
was replaced by serum-free medium. Forty-eight hours after serum depriva-
tion, cells were cultured in the presence or absence of inducers for 12, 24, or
48 h. Hepatocytes were treated with rifampicin (5 M), atorvastatin (10 M),
rosuvastatin (10 M), or LK-935 (10 M).
P450 Enzyme Assays. Microsomal fraction from cultured human hepato-
cytes was prepared by differential centrifugation (van der Hoeven and Coon,
1974). Protein content of microsomes was determined by the method of Lowry
et al. (1951), with bovine serum albumin as the standard. Published methods
were followed to determine selective P450 enzyme activities: (S)-mephenytoin
N-demethylation for CYP2B6 (Heyn et al., 1996), tolbutamide 4-hydroxyla-
tion for CYP2C9 (Miners and Birkett, 1996), (S)-mephenytoin 4-hydroxyla-
tion for CYP2C19 (Srivastava et al., 1991), and nifedipine oxidation
(Guengerich et al., 1986) for CYP3A4/5. The incubation mixture contained an
NADPH-generating system (1 mM NADPH, 10 mM glucose 6-phosphate, 5
mM MgCl2, and 2 units/ml glucose-6-phosphate dehydrogenase), microsomes,
and various selective substrates for P450 forms [(S)-mephenytoin, tolbutamide,
or nifedipine]. The rates of enzyme activities were linearly dependent on the
amount of microsomal protein added for the 10- to 30-min incubation period.
The metabolic extraction procedures and high-performance liquid chromatog-
raphy analyses were performed according to published methods (Guengerich et
al., 1986; Srivastava et al., 1991; Heyn et al., 1996; Miners and Birkett, 1996).
P450 enzyme assays were performed in triplicate and means  S.D. were
calculated. For comparison among untreated and treated groups, statistical
analysis of the results was carried out using a two-tailed t test with p  0.05
as the criterion for significance. Because of the high variation in basic P450
expression of human hepatocytes, the entire experiment was repeated in
hepatocytes isolated from four to seven donors to confirm the results.
RNA Extraction and Quantitative RT-PCR. Total RNA was isolated
from human hepatocytes using TRIzol reagent (Invitrogen, Carlsbad, CA). Ten
million liver cells were homogenized in 1 ml of TRIzol reagent, and total RNA
was extracted according to the manufacturer’s instructions. The RNA was
precipitated using ethanol and stored at 80°C for further analyses. RNA (3
g) was reverse-transcribed into single-stranded cDNA using a Transcriptor
First Strand cDNA synthesis kit (Roche Diagnostics GmbH, Mannheim, Ger-
many), and then real-time PCR with human cDNA was performed using
FastStart Taq DNA polymerase (LightCycler TaqMan Master; Roche Diag-
nostics GmbH) and probes for CYP2B6, CYP2C9, CYP2C19, and CYP3A4
(Universal ProbeLibrary kits; Roche Diagnostics GmbH). The quantity of
target RNA relative to that of the housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase was determined. P450 mRNA levels were quantified by
RT-PCR measurements in the same human hepatocytes in which P450 activ-
ities were measured. Statistical analysis of the results obtained by RT-PCR was
preformed similarly to that of P450 activities.
Western Blot Analysis. Microsomal proteins prepared from human hepa-
tocytes (2.5 g/lane) were separated by SDS-polyacrylamide gel electrophore-
sis using 12% acrylamide. The gels were shaken in transfer buffer [40 mM
glycine, 50 mM Tris (pH 8.3), 0.04% SDS, and 20% methanol] for 20 min
before electroblotting onto a nitrocellulose membrane (GE Healthcare,
Freiburg, Germany). For blocking, the membrane was incubated for 1 h in
Tris-buffered solution (TBS) containing 5% nonfat dried milk and 0.1% Tween
20. Incubation with monoclonal mouse anti-human CYP3A (BD Gentest,
Heidelberg, Germany) diluted 1:5000 in TBS containing 0.1% Tween 20 was
performed for 2 h. After the blots were washed three times for 30 min in
phosphate-buffered saline, they were exposed to the horseradish peroxidase-
conjugated rabbit anti-mouse antibody (Dako Deutschland GmbH, Hamburg,
Germany) in a dilution of 1:1000 in TBS containing 0.1% Tween 20. Three
washing steps for 30 min in phosphate-buffered saline were done before the
blots were exposed to Hyperfilm ECL (GE Healthcare) and the ECL Plus
Western blotting reagents (GE Healthcare) following the manufacturer’s
instructions.
Cell Culture and Transfection. HepG2 cells were maintained in DMEM
supplemented with 10% fetal calf serum, 1 mM glutamine, 10 mM sodium
pyruvate, and 100 g/ml penicillin and streptomycin. Transient transfections
with 10 ng of expression plasmid containing hPXR or hCAR together with 100
ng of luciferase reporter constructs pGL3(CYP3A4/XREM[7800/7200]/
263/11)LUC were performed in batches on 5  104 cells seeded into
24-well tissue culture plates using FuGENE 6 transfection agent (Roche
Diagnostics, Basel, Switzerland) as described previously (Pascussi et al.,
2003a). After 16 h, the medium was changed, and the cells were treated with
atorvastatin (10 M), rosuvastatin (10 M), LK-935 (10 M), rifampicin (3
M), or solvent [0.1% dimethyl sulfoxide (DMSO)] in DMEM containing 5%
delipidated and charcoal-treated calf serum. After a 24-h incubation, luciferase
activities were measured as described previously (Pascussi et al., 2003a).
Values are expressed as the mean  S.D. for three experiments measured in
triplicate. Reporter gene activity of the DMSO-treated cells served as a control
and was set to unity.
In Vitro Kinetics of LK-935. Biotransformation of LK-935 was performed
in a cell suspension (1.7  106 cells/ml) at 37°C in a humid atmosphere
containing 5% CO2. The parent compound was added directly to the medium
(final concentration of LK-935: 1 and 10 M). Aliquots (0.5 ml) of the
incubation mixtures were terminated by the addition of 0.5 ml of ice-cold
acetonitrile at 0, 2, 4, 6, 8, 10, 15, 20, and 25 min, and the samples were stored
at 80°C. Cell debris was separated by centrifugation, and 10 l of the
supernatant was analyzed by LC-MS/MS for quantitation of the parent com-
pound. For this purpose, an ODS-AQ 20  2.1 mm (5 m) column (YMC
TABLE 1
Clinical histories of human donors
Donor Age Sex Race COD/Disease State
year
HH-089 44 Female White COD: subarachnoidal hemorrhage
HH-114 57 Female White COD: rupture of aneurism
HH-129 49 Female White COD: stroke
HH-269 46 Male White Hepatocellular carcinoma
HH-270 57 Male White Metastasis of colon cancer
HH-271 56 Female White Metastasis of colon cancer
HH-272 20 Male White COD: subarachnoidal hemorrhage
COD, cause of death.
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Europe GmbH, Dimslaken, Germany) was used. Gradient elution was applied
with mobile phase A consisting of 10 mM ammonium-formate and with
acetonitrile as mobile phase B. The column was eluted at a rate of 0.4 ml/min
at 40°C, and the effluent was analyzed by mass spectrometry. MS/MS mea-
surements were obtained on a 3200 Qtrap hybrid (quadrupole-linear ion trap)
tandem mass spectrometer (Applied Biosystems, Foster City, CA) equipped
with a TurboV ion source. The ionization mode was electrospray in positive
mode. The instrument was scanned in enhanced product ion (EPI) mode for
structure identification and in multiple reaction monitoring (MRM) mode for
quantitation. The source conditions were as follows: curtain gas, 35 units;
spray voltage, 5000 V; source temperature, 350°C; nebulizing gas GS1, 50
units; drying gas GS2, 40 units; and declustering potential, 30 V. Two MRM
transitions (the first transition as the quantifier and the second as the qualifier
channel), 353/173 (collision energy: 37 eV) and 353/137 (collision energy: 49
eV), were monitored for LK-935 with dwell time of 150 ms.
Estimation of Clearance. The intrinsic clearance for hepatocytes (Clint)
(ml/min/1.7  106 cells) was calculated from the decrease in the concentration
of LK-935 as follows: Clint    (ln2/t1/2) (Houston, 1994). For scaling up
the Clint value to obtain Clint per whole liver (g)/bw (kg), the following parameters
were used: cell concentration in liver, 1.07  108 cells/1 g of liver (Wilson et
al., 2003); average human liver weight, 1660 g; and average human body
weight, 70 kg. The value for hepatic clearance (ClH) was calculated as follows:
ClH 
Clint liverbw  fu  Qplasma
	Clint liverbw  fu
  Qplasma
where Qplasma  QH  plasma/blood ratio. To calculate ClH, QH  19 ml of
blood/min/kg, plasma/blood ratio  0.57, and fu  1 values were used, where
QH is the hepatic blood flow, and fu is the unbound fraction of the compound.
The hepatic extraction ratio was defined as E  ClH  QH.
Identification of LK-935 Metabolites. The chemical structures of LK-935
metabolites were determined in the incubation mixture using human hepato-
cytes. The analytical conditions were the same as those described for the parent
compound. Metabolites were initially characterized by LC-MS/MS in full scan
mode by comparing 0-min samples with 60-min samples. To improve sensi-
tivity, the metabolites were also characterized using the MRM mode in which
the MRM transitions of the parent drug were modified according to the mass
shifts of the metabolites comparing with LK-935.
Inhibition Studies. Metabolite formation from LK-935 was determined in
human liver microsomes. The incubation mixture contained the NADPH-
generating system (1 mM NADPH, 10 mM glucose 6-phosphate, 5 mM
MgCl2, and 2 units/ml glucose-6-phosphate dehydrogenase), human liver
microsomes (1 mg of protein/ml), and LK-935 at various concentrations. After
a 20-min incubation, reactions were terminated by the addition of ice-cold
acetonitrile. The amounts of LK-935 metabolites produced were determined by
LC-MS/MS. The analytical conditions were the same as those described for the
parent compound except for the MRM transitions and collision energies, which
were 311/173 (37 eV) and 311/137 (49 eV) for M1, 232/137 (45 eV) and
232/173 (45 eV) for M2, and 369/173 (45 eV) and 369/189 (45 eV) for M3.
Inhibition of metabolite formation from LK-935 was carried out in the absence
and presence of various P450 inhibitors (pentoxyresorufin for CYP2B6, sul-
faphenazole for CYP2C9, tranylcypromine for CYP2C19, and ketoconazole
for CYP3A4/5) (Bourrie´ et al., 1996; Ono et al., 1996; Salsali et al., 2004). Ki
values (inhibition constants) were determined by using different concentrations
of LK-935 (5, 10, and 20 M) and inhibitors (0.2–10 M). Ki values were
calculated from Dixon plots of velocity1 versus inhibitor concentration at the
three LK-935 concentrations. The type of inhibition and the apparent Ki values
were estimated from the intercept of three lines of Dixon plots and expressed
as the mean  S.D. of the intercepts.
Statistical Analysis. For comparison among several groups, statistical
analysis of the results obtained in the experiments with human hepatocytes and
in cell line transfection was carried out using a paired two-tailed t test with p 
0.05 as the criterion for significance (GraphPad InStat version 3.0; GraphPad
Software, San Diego, CA).
Results
Sterol Profile of HepG2 Cells Treated with LK-935. De novo
biosynthesis of cholesterol was determined in HepG2 cells after
incubation with [3H]acetate. 3H-labeled sterol components of the
postlanosterol part of cholesterol biosynthesis were isolated from the
cells treated with LK-935 and two well known statins, atorvastatin and
rosuvastatin. De novo synthesis of lanosterol, FF-MAS, lathosterol,
7-dehydrocholesterol, desmosterol, and cholesterol in treated cells
was compared with that in untreated cells. Although the chemical
structures of these sterols are similar, they can be separated and
unequivocally identified using the reference standards. De novo pro-
duced cholesterol represented approximately 20% of the radiolabeled
sterol pool, whereas lanosterol and lathosterol were the two major
sterol intermediates with 25% of each. LK-935, being an efficient
inhibitor of CYP51 (Korosec et al., 2008), caused a substantial accu-
mulation of lanosterol and completely blocked the formation of cho-
lesterol and postlanosterol intermediates (Fig. 1B). As was expected,
neither cholesterol nor the sterol intermediates were produced in the
cells treated with atorvastatin, the potent HMG-CoA reductase inhib-
itor. Rosuvastatin treatment also decreased the formation of lanos-
terol, cholesterol, and the intermediates between them; however,
rosuvastatin did not seem to be as efficient a HMG-CoA reductase
inhibitor as atorvastatin possibly because of its more hydrophilic
character.
P450 Induction by LK-935 and Reference Statins in Human
Hepatocytes. The P450-inducing potential of statin-type cholesterol-
lowering agents is one of the sources of clinically relevant drug-drug
interactions. Atorvastatin has been reported to increase the expression
of CYP2B6 and CYP3A4 (Kocarek et al., 2002), whereas the capa-
bility of rosuvastatin for P450 induction has been poorly described. To
determine whether LK-935 treatment results in changes in the expres-
sion of the main drug-metabolizing P450s, we investigated the effect
of LK-935 in primary culture of human hepatocytes. We wished to
extend the studies on CYP2C9 and CYP2C19 in addition to CYP2B6
and CYP3A4. P450 enzyme activities and mRNA levels were deter-
mined in primary hepatocytes isolated from several donors (as indi-
cated in Figs. 2 and 3) because of high individual variance in basic
activities or P450 expression of the cells. To improve our knowledge
about the P450 inducibility of human liver cells by the most fre-
quently used antihyperlipidemic drugs, atorvastatin and rosuvastatin
were also involved in our experiments. Because both of these statins
and LK-935 efficiently inhibited de novo cholesterol biosynthesis at
10 M, we applied this concentration in further experiments. Rifam-
picin was used as a reference compound at the concentration of 5 M.
Rifampicin binds to and strongly activates PXR, leading to induction
of P450s such as CYP3A4 (Luo et al., 2002). To evaluate the signif-
icant inducibility of human hepatocytes by the statins and LK-935, a
paired t test was performed with p  0.05 as the criterion for
significance. Figures 2 and 3 present mRNA levels and P450 activities
relative to control hepatocytes (0.1% DMSO-treated cells).
In each human hepatocyte preparation, treatments with atorvastatin
and rosuvastatin, but not with LK-935, increased the expression of
CYP2B6 and CYP2C9 even at the 12-h time point (Fig. 2, A and B).
The statistically significant induction as a result of atorvastatin treat-
ment was similar or somewhat lower than that observed in rifampicin-
treated hepatocytes. The elevation of mephenytoin N-demethylation
of CYP2B6 and tolbutamide hydroxylation activity of CYP2C9 was
nearly concomitant with the fold changes in mRNA levels of atorv-
astatin-treated cells (Fig. 3A). The CYP2B6- and CYP2C9-inducing
potential of rosuvastatin seemed to be milder than that observed in
rifampicin- or atorvastatin-treated cells. Although rosuvastatin ele-
vated the levels of CYP2B6 and CYP2C9 mRNAs by approximately
3- to 4-fold relative to the control, mephenytoin N-demethylation and
tolbutamide hydroxylation did not seem to be substantially induced.
Neither the statins nor LK-935 produced any consistent effect on
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CYP2C19 expression and mephenytoin 4-hydroxylation activity. Ri-
fampicin was the only agent that was able to increase mRNA level and
activity of CYP2C19 (Figs. 2C and 3A).
Nifedipine oxidation of CYP3A4 increased by more than 30-fold in
rifampicin-treated cells (Fig. 3A). Rifampicin was also demonstrated
to produce strong transcriptional activation of the CYP3A4 gene (more
than 60-fold after a 48-h exposure) (Fig. 2D), involving the action of
nuclear receptor PXR. Treatments with atorvastatin resulted in an
approximately 10-fold induction of CYP3A4 activity, whereas rosu-
vastatin caused a 2- to 4-fold increase in nifedipine oxidation in
hepatocytes isolated from various donors (Fig. 3A). The elevation in
enzyme activities was confirmed by the changes in levels of CYP3A4
mRNA as a consequence of statin treatments (Fig. 2D). The maximal
increase in the transcription of the CYP3A4 gene was generated after
a 24-h exposure to atorvastatin or rosuvastatin. Nifedipine oxidation
activity and expression of CYP3A4 were significantly induced by
LK-935 (Figs. 2D and 3A). However, the degree of the elevation of
CYP3A4 activity and mRNA levels relative to the control cell pop-
ulation (1.75- and 2.5-fold, respectively) was far from those produced
by statins or rifampicin. The results of Western blot analysis of
microsomal proteins isolated from the hepatocytes treated with statins,
LK-935 or rifampicin, confirmed our findings regarding CYP3A4
induction (as a representative example, see Fig. 3B). As expected,
rifampicin treatment resulted in an abundant expression of CYP3A
protein. The statin-treated cells showed a marked increase in the
amount of CYP3A immunoreactive protein, whereas LK-935 treat-
ment resulted in a mild, but definite, increase in CYP3A protein.
Activation of hPXR and hCAR by the Statins and LK-935.
Atorvastatin is known to induce the expression of CYP3A4 through
the activation of PXR. Atorvastatin is also an activator of CAR that
mediates the induction of CYP2B6 expression (Kocarek et al., 2002;
Kobayashi et al., 2005). Both PXR and CAR have been demonstrated
to be involved in regulation of several P450s (CYP2B6, CYP2C9,
CYP2C19, and CYP3A4) in humans (Chen et al., 2003; Pascussi et
al., 2003b). Our results demonstrate the induction of both the activities
and the expression of CYP2B6, CYP2C9, and CYP3A4 by atorvasta-
tin in human hepatocytes, thus confirming the findings of Kocarek et
al. (2002) and of Kobayashi et al. (2005). The P450-inducing profile
of rosuvastatin-treated hepatocytes suggested that rosuvastatin in-
volved the action of nuclear receptor(s) in transcriptional activation of
P450 genes. We also attempted to elucidate the role of nuclear
receptors, PXR and CAR, in the induction exerted by LK-935.
To assess whether rosuvastatin and LK-935 are able to activate
human PXR or CAR, transient cotransfection assays were performed
in HepG2 cells. The effect on transcriptional activation of hPXR and
hCAR was investigated using a reporter plasmid [pGL3(CYP3A4/
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FIG. 2. Induction of CYP2B6 (A), CYP2C9 (B), CYP2C19 (C), and CYP3A4 (D) mRNA expression in primary human hepatocytes. Primary human hepatocytes were
treated for 12, 24, and 48 h with rifampicin (RIF; 5 M), atorvastatin (ATV; 10 M), rosuvastatin (RSV; 10 M), and LK-935 (10 M). mRNA levels in human hepatocytes
(n  7 donors) were quantified and normalized to glyceraldehyde-3-phosphate dehydrogenase as described under Materials and Methods. Error bars represent means 
S.D. of seven donors.
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XREM[7800/7200]/263/11)LUC] containing the distal xeno-
biotic-responsive element module (XREM, 7800/7200) linked to
the proximal CYP3A4 promoter (263/11). The reporter plasmid
was cotransfected with hPXR or hCAR. Atorvastatin was able to
markedly activate the reporter plasmid cotransfected with hPXR, but
the extent of PXR activation was lower (5.5-fold) than that observed
in the cells exposed to rifampicin (9-fold) (Fig. 4). Rosuvastatin did
not seem to activate hPXR, supposing the involvement of other
nuclear receptors in P450 induction. LK-935 treatment resulted in a
potent increase in ligand-induced transactivation of the reporter con-
struct by hPXR. The 9-fold induction observed at 10 M LK-935 was
identical to the increase in luciferase activity caused by the well
known PXR agonist rifampicin (Luo et al., 2002). From the fact that
LK-935 was as potent a PXR agonist as rifampicin, we may assume
strong induction of several P450s, especially of CYP3A4. In contrast
to this finding, we observed only a mild increase in the activity and
expression of CYP3A4 in LK-935-treated human hepatocytes.
Atorvastatin, rosuvastatin, and LK-935 were also screened in a
HepG2 cell-based reporter gene assay transfected with hCAR and a
CYP3A4/XREM[7800/7200]/263/11 reporter gene construct.
As shown in Fig. 4, both statins increased hCAR-mediated transcrip-
tional activity (atorvastatin by 2.8-fold and rosuvastatin by 1.8-fold).
The effects of LK-935 and rifampicin on the CAR-mediated transcrip-
tional activity were found to be negligible and not significant. It is
consistent with our knowledge that rifampicin is a potent hPXR
agonist but does not activate hCAR.
Metabolism of LK-935 by Primary Human Hepatocytes. In
HepG2 cell-based reporter gene assays, LK-935 was demonstrated to
be as potent an hPXR activator as rifampicin. On the other hand, the
degree of CYP3A4 induction by LK-935 in primary human hepato-
cytes was far from the effect of rifampicin. From these findings and
the fact that the metabolic capacity of HepG2 cells is less than that of
primary hepatocytes, we may assume rapid metabolism of LK-935 in
primary liver cells and, consequently, rapid reduction of the effective
concentration required for PXR activation. To confirm our assump-
tion, biotransformation of LK-935 (1 and 10 M) was determined in
suspension of primary human hepatocytes isolated from three donors.
Extensive metabolism was observed in human liver cells. After 25
min, more than 80% of the initial concentration of 1 M was metab-
olized (Fig. 5), whereas less than 50% of the starting concentration of
10 M LK-935 remained unchanged. The elimination half-life was
estimated to be 6.06 and 23.6 min at the concentrations of 1 and 10
M, respectively (Table 2). On the basis of the pharmacokinetic
parameters estimated in the in vitro hepatocyte system, LK-935 was
considered to be a biologically unstable drug. It should be noted that
LK-935 was proved to be chemically stable, because no loss of the
substrate was observed in the medium in the absence of hepatocytes.
The LC-MS/MS analysis of the incubation mixture with LK-935
revealed six metabolites (M1, M2, M3a, M3b, M4a, and M4b) pro-
duced by primary human hepatocytes (Fig. 6). All metabolites were
eluted earlier than LK-935, indicating that the LK-935 derivatives had
more hydrophilic properties than the parent compound. The MS/MS
spectrum of LK-935 obtained by the EPI scan technique displayed an
abundant peak of protonated molecular ion (M  H) at m/z 353 and
main fragment peaks at m/z 335 (water loss), at m/z 293 (loss of the
propyl group), and at m/z 244 (cleavage of the C–C bond at the
hydroxyl group). Further characteristic fragments of LK-935 were at
m/z 173 formed by the cleavage of the N–C bond containing the
chloro-substituted phenyl ring and at m/z 137 and 102 formed by the
consecutive loss of HCl and Cl from the ion 173 (Fig. 7).
The MS/MS analysis revealed the structure of M1 formed by
cleavage of the propyl group from the central nitrogen of LK-935
(Fig. 7). The mass shift of M1 with m/z 311 (M  H) was 42 Da
compared with LK-935. The EPI spectrum of M1 was similar to that
of the parent compound (fragments at m/z 293, 173, 137, and 102).
The minor peak at m/z 202 was considered to be the analog of the ion
244 in the EPI spectrum of the parent drug with the mass difference
of 42 Da originating from the lack of propyl chain. The derivative
with m/z 232 (M  H) displayed a mass shift of 121 Da, corre-
sponding to M2 formed by the cleavage of hydroxyethyl-pyridine
moiety from the central nitrogen of LK-935. The EPI spectrum of M2
showed the ions at m/z 173, 137, and 102. During screening for m/z
369 (M  H) corresponding to the mass shift of 16 Da, two
metabolites (M3a and M3b) were detected, indicating monohydroxy
derivatives of LK-935. It was supported by the fragment ions at m/z
351 and 333, representing consecutive losses of two H2O. The EPI
spectrum of M3a showed a fragment ion at m/z 260, whereas that of
M3b displayed an intense ion at m/z 244. Further characteristic frag-
ments of M3 metabolites were at m/z 173, 137, and 102, indicating
that the dichloro-phenyl-ethyl moiety of both monohydroxy metabo-
lites was intact. We assumed that the ion at m/z 244 in the EPI
spectrum of LK-935 was formed after the loss of the hydroxyethyl-
pyridine part; thus, the M3a metabolite producing the fragment ion at
m/z 260 (with mass shift of 16 Da comparing with m/z 244)
contained the hydroxyl group at the propyl group. From these data, it
can be concluded that the hydroxylation of LK-935 producing M3b
took place at the pyridine ring. M4a and M4b as minor metabolites
were detected at m/z 248 (M  H), presenting the mass shift of 16
Da compared with M2. The water loss of 18 Da in the EPI spectrum
proposed that the structure of M4 metabolites was the hydroxylated
derivatives of M2. The presence of the fragment ion series 173, 137,
and 102 suggested that the dichloro-phenyl-ethyl moiety was intact
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FIG. 3. Induction of CYP2B6, CYP2C9, CYP2C19, and CYP3A4 enzymes in
primary human hepatocytes. A, primary human hepatocytes were treated for 48 h
with rifampicin (RIF; 5 M), atorvastatin (ATV; 10 M), rosuvastatin (RSV; 10
M), and LK-935 (10 M). P450 activities were determined in microsomes pre-
pared from hepatocytes isolated from four donors. Controls (C) for each indepen-
dent experiment were assigned values of 1, and results of treatments are expressed
relative to the controls. B, CYP3A4 enzyme protein was determined by Western blot
analysis as described under Materials and Methods. Representative examples for
CYP3A4 protein content in HH-089 cells are presented.
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and the hydroxy-group was likely to locate at one of the carbon of the
propyl group. For M4a, the additional ions at m/z 175, 161, and 139
derived from an isoxazolidine loss suggested the position of the
hydroxy group at the terminal carbon atom.
Involvement of P450 Forms in LK-935 Metabolism. Various
P450 inhibitors (ketoconazole for CYP3A4, sulfaphenazole for
CYP2C9, tranylcypromine for CYP2C19, and pentoxyresorufin for
CYP2B6) were used to identify the individual isozymes participating
in the formation of LK-935 metabolites (Table 3). The contributions
of P450 isoforms to the production of LK-935 derivatives were
characterized by inhibition constants (Ki values) determined at various
concentrations of LK-935 (5, 10, and 20 M) and of chemical
inhibitors. The production of M1 was strongly reduced in the presence
of ketoconazole and sulfaphenazole, suggesting contributions of
CYP3A4 and CYP2C9 to the cleavage of the propyl group from the
central nitrogen of LK-935. Dixon plots displayed the competitive
inhibition of M1 formation both by ketoconazole and by sulfa-
phenazole. Ketoconazole was also found to be a potent competitive
inhibitor of M2 formation with a submicromolar Ki value, providing
evidence for the role of CYP3A4. Chemical inhibition of CYP2C9,
CYP2C19, and CYP2B6 did not decrease the rate of cleavage of the
hydroxyethyl-pyridine moiety from LK-935. Sulfaphenazole selective
for CYP2C9 seemed to be a potent competitive inhibitor of LK-935
hydroxylation at the propyl-group (M3a formation) and at the pyridine
ring (M3b formation). Ketoconazole also seemed to decrease M3b
production; however, with a Ki value one magnitude higher than that
of sulfaphenazole. In conclusion, the results of chemical inhibition
studies indicated a possible involvement of CYP2C9 and CYP3A4 in
the metabolism of LK-935, whereas the contributions of CYP2B6 and
CYP2C19 were not confirmed (Fig. 7).
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FIG. 5. In vitro kinetic analysis of LK-935 in primary human hepa-
tocytes. LK-935 at the concentration of 1 M was incubated in
hepatocytes isolated from three donors. The consumption of LK-
935 as a function of time was determined by LC-MS/MS as de-
scribed under Materials and Methods.
TABLE 2
Kinetic parameters for LK-935 metabolism by primary human hepatocytes
Parameter 1 M 10 M
t1/2 (min) 6.06  2.35 23.6  4.93
Clint (ml/min/kg) 198.7  67.32 47.96  9.97
ClH (ml/min/kg) 10.2  0.22 8.8  0.35
E (extraction ratio) 0.944 0.815
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FIG. 4. Activation of hPXR and hCAR in response to statins,
LK-935, and the PXR agonist rifampicin. HepG2 cells were tran-
siently transfected with expression plasmid (pSG5-hPXR or pSG5-
hCAR) together with luciferase reporter construct pGL3(CYP3A4/
XREM[7800/7200]/263/11)LUC expression plasmid. The
cells were treated for 24 h with rifampicin (3 M), atorvastatin (10
M), rosuvastatin (10 M), and LK-935 (10 M). Luciferase
activities were determined as described under Materials and
Methods.
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Discussion
Because of the increasing instances of hyperlipidemias and cardio-
vascular diseases in the developed world and the risk of severe
adverse drug reactions (myopathies, rhabdomyolysis, renal toxicity,
and hepatotoxicity) with statin-based therapy, development of novel
strategies in cholesterol-lowering therapy is greatly needed (Tiwari et
al., 2006; Alsheikh-Ali et al., 2007; Armitage, 2007; Martin and
Krum, 2007; Rallidis et al., 2007). Searching for potential hypolipi-
demic drugs with new molecular targets is an important task for the
pharmaceutical industry. The novel cholesterol-lowering drug candi-
dates block cholesterol biosynthesis after the farnesyl pyrophosphate
branchpoint, leaving the isoprene pathways untouched to avoid statin
side effects (Fig. 1A) (Korosec et al., 2008). LK-935, a pyridyleth-
anol(phenylethyl)amine derivative targeting human lanosterol 14-
demethylase (CYP51), was demonstrated to efficiently inhibit post-
squalene cholesterol biosynthesis. The aim of our study was to reveal
the drug interaction potential of LK-935 and to predict the P450-
mediated interactions with coadministered drugs. We, therefore, in-
vestigated the induction of P450s by LK-935 in primary cultures of
human hepatocytes and compared its P450-inducing potential with
that of two frequently used statins, atorvastatin and rosuvastatin.
Atorvastatin, being an activator of hPXR and hCAR, has been
reported to induce CYP3A4 and CYP2B6 (El-Sankary et al., 2001;
Kocarek et al., 2002; Kobayashi et al., 2005). The results of the
current studies provided unequivocal evidence that, in addition to
these enzymes, the transcriptional expression and tolbutamide hy-
droxylation activity of CYP2C9 also increased in atorvastatin-treated
hepatocytes. Rosuvastatin treatment also elevated the expression and
activities of CYP3A4, CYP2C9, and CYP2B6; however, rosuvastatin
did not seem to be as potent a P450 inducer as atorvastatin. In
investigation of the role of nuclear receptors in rosuvastatin action,
hCAR, but not hPXR, was supposed to mediate the increase in P450
expression (Fig. 4). LK-935, though, seemed to be a weak inducer in
comparison with the statins or rifampicin, and the treatment of human
hepatocytes with LK-935 led to up-regulation of CYP3A4, suggesting
the involvement of PXR. In HepG2 cell-based assays, LK-935 proved
to strongly activate hPXR; moreover, it seemed to be as potent a PXR
activator as the well known PXR agonist rifampicin (Luo et al., 2002).
The fact that LK-935 is an efficient agonist of hPXR is inconsistent
with the findings of P450 induction studies, demonstrating a mild
increase in CYP3A4 expression in primary hepatocytes as a conse-
quence of LK-935 treatment. This inconsistency was assumed to be
explained by the differences in the drug-metabolizing capacity be-
tween HepG2 cells and primary human hepatocytes. The activities and
the expression of drug-metabolizing P450s have been demonstrated to
be extremely low in HepG2 cells (Wilkening et al., 2003). In contrast,
primary human hepatocytes were proved to extensively metabolize
LK-935, rapidly decreasing the effective concentration presumably
required for the maximal PXR activation. CYP3A4 and CYP2C9 were
found to play a major role in the biotransformation of LK-935.
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TABLE 3
Inhibition of LK-935 metabolism by chemical inhibitors
Inhibitor
Ki Values
M1 M2 M3a M3b
M
Ketoconazole (CYP3A4) 1.33  0.65 0.788  0.063 NI 12.8  4.09
Pentoxyresorufin (CYP2B6) NI NI NI NI
Sulfaphenazole (CYP2C9) 1.56  0.97 NI 0.617  0.195 1.04  0.009
Tranylcypromine (CYP2C19) NI NI NI NI
NI, not inhibited.
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CYP3A4, the most abundant isozyme of all P450s in human liver, is
not detectable in HepG2 cells, and the expression of CYP2C9 is also
negligible in this cell line (Wilkening et al., 2003).
Primary hepatocytes offer a useful model for estimation of in vitro
pharmacokinetic properties of a drug and for prediction of in vivo
pharmacokinetic parameters for most drugs. The predictability of in
vivo Clint from in vitro data is considered to be good, even for drugs
with in vivo Clint values ranging over 4 orders of magnitude. For
LK-935 at the concentrations of both 1 and 10 M, extremely high
Clint values were estimated in primary human hepatocytes (198.7 and
47.96 ml/min/kg, respectively). The model (ClH) accounting for the
influence of the metabolic (in vitro Clint) and nonenzymatic [binding
to plasma proteins and hepatic blood flow (QH): 19 and 10.8 ml of
plasma/min/kg, respectively] factors estimated LK-935 to be a high-
extraction drug with low bioavailability (extraction ratios of 0.944 and
0.815 for 1 and 10 M, respectively).
The in vitro pharmacokinetic studies using primary human hepato-
cytes also generated samples for the identification of metabolites.
During the biotransformation, LK-935 underwent predominantly N-
dealkylation and hydroxylation to a lesser extent. The cleavage of the
propyl group from the tertiary amine of LK-935 resulted in the
formation of M1, whereas the cleavage of the hydroxyethyl-pyridine
part produced the major M2 metabolite. LC-MS/MS analysis identi-
fied two monohydroxy derivatives of LK-935 (M3 metabolites). One
of them contained the hydroxy group at the propyl group and the other
on the pyridine ring. The metabolite profile assumed that the main M2
metabolite underwent further hydroxylation at the propyl group, lead-
ing to the formation of two minor M4 metabolites (M4a and M4b). In
vitro inhibition studies implicated CYP3A4 and CYP2C9 in the
oxidative metabolism of LK-935. CYP3A4 seemed to have a signif-
icant role in the formation of the main metabolite M2. Clear evidence
was provided for the participation of CYP2C9 in the hydroxylation of
LK-935, whereas CYP3A4 and CYP2C9 seemed to account for equal
contributions to the cleavage of the propyl group from the central
nitrogen of LK-935.
In conclusion, we provide evidence for the induction of CYP3A4
by the novel cholesterol-lowering drug candidate LK-935. LK-935
has also been proved to be a potent hPXR activator as prerequisite for
the transcriptional activation of the CYP3A4 gene; however, the rapid
metabolism of LK-935 in primary hepatocytes decreases the efficient
concentration required for maximal CYP3A4 induction. Therefore,
the induction of CYP3A4 by LK-935 would be taken into account as
the source of a mild or negligible drug-drug interaction. However,
because CYP3A4 and CYP2C9 play a significant role in LK-935
metabolism, the inhibition of these P450s by coadministered drugs
may lead to some increase in the LK-935 concentration required for
the potent induction of CYP3A4. Our results also suggested the
activation of hCAR by rosuvastatin and consequently for the induc-
tion of CYP3A4, CYP2C9, and CYP2B6 genes. The inductive response
to rosuvastatin treatment can be the source of drug-drug interactions.
Activation of hCAR and hPXR by atorvastatin and the subsequent
induction of not only CYP2B6 and CYP3A4 but also CYP2C9 present
additional targets by which atorvastatin, a widely used cholesterol-
lowering drug, can modify the kinetics of numerous drugs.
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